ca41a924-f82c-4e83-996b-35261387ad3a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 82
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.400
- CHOLESTEROL_HOMEOSTASIS+0.270
- HEDGEHOG_SIGNALING+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- NOTCH_SIGNALING+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.180
- MYC_TARGETS_V2+0.170
- MYC_TARGETS_V1+0.150
- ANDROGEN_RESPONSE+0.140
- ESTROGEN_RESPONSE_EARLY+0.120
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.320
- IL6_JAK_STAT3_SIGNALING-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- E2F_TARGETS-0.300
- ANGIOGENESIS-0.270
- INTERFERON_GAMMA_RESPONSE-0.270
- G2M_CHECKPOINT-0.260
- INFLAMMATORY_RESPONSE-0.220
- COMPLEMENT-0.210
- UV_RESPONSE_DN-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8a0acec7-896e-4c91-8ce7-dc64de45b53d | — | — | 0.702 |
| 2 | MNG124 | — | — | 0.698 |
| 3 | DRR168523 | — | — | 0.688 |
| 4 | TCGA-B6-A0X0-01A-21R-A115-07 | — | B | 0.679 |
| 5 | MNG127 | — | — | 0.674 |
| 6 | DRR168554 | — | — | 0.668 |
| 7 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.665 |
| 8 | DRR168551 | — | — | 0.661 |
| 9 | TCGA-UF-A71E-01A-31R-A34R-07 | — | — | 0.661 |
| 10 | SRR8392893 | — | cohortSQ2 | 0.659 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |